Opendata, web and dolomites

PREDICT SIGNED

Big Data EEG-Analysis for Advanced Personalised Medicine in Depression

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PREDICT project word cloud

Explore the words cloud of the PREDICT project. It provides you a very rough idea of what is the project "PREDICT" about.

error    diagnosis    percentage    biomarkers    determines    eluded    day    treatments    health    delays    medicine    ranges    individual       treat    98    accounting    mdd    personalised    symptoms    mental    compare    remission    invasive    temperature    modern    population    event    unable    therapies    ailments    tms    predicts    treatment    healthcare    heavy    diagnose    33    validated    costly    amelioration    slows    receiving       prescribed    prevents    fat    quality    equivalent    cholesterol    substantiation    time    life    countless    people    suffer    disorders    rarely    body    tool    electroencephalogram    dramatically    predict    functions    patients    rates    truly    gdp    metrics    right    organ    weight    accurately    savings    trial    depressive    quantifying    easily    ownership    52    million    responsiveness    measured    normal    measuring    suspected    improves    doctors    brain    total    disorder    hinders    elminda    reduces    brains    patient    antidepressants    psa    equal   

Project "PREDICT" data sheet

The following table provides information about the project.

Coordinator
ELMINDA LTD 

Organization address
address: Shenkar 1, WeWork Building
city: HERZLIYA
postcode: 4673314
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙798˙450 €
 EC max contribution 1˙958˙915 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ELMINDA LTD IL (HERZLIYA) coordinator 1˙958˙915.00

Map

 Project objective

Modern medicine has given us countless methods of understanding, measuring and managing such metrics of our health as temperature, weight, body fat percentage, cholesterol, PSA values, etc. A patient’s measured values are easily compared against well-established normal ranges. And yet a simple, non-invasive method for measuring and quantifying the health of our brains has eluded us. Being unable to accurately measure and compare how a brain functions hinders doctors’ ability to diagnose and treat suspected ailments. It also slows the substantiation of new therapies. And, just as importantly, it prevents each of us from truly understanding and taking ownership of the health of our body’s most important organ. Major Depressive Disorder (MDD) has been identified as the leading and most costly mental disorder, accounting for 33% of the total cost of brain disorders, and equal to 1% of the GDP. Each year, about 7% of the population suffer from MDD in Europe, equivalent to 52.98 million people. The current methods of treatment are prescribed through trial and error with patients rarely receiving the ‘right’ treatment from day one. This reduces response rates and delays remission, which has a heavy impact on the individual’s quality of life. elminda has developed the “PREDICT” tool which predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms for MDD patients. PREDICT determines personalised treatments for MDD patients based on validated electroencephalogram and event-related potential brain-related biomarkers. The tool predicts responsiveness to antidepressants and TMS treatment, and thus dramatically reduces time from diagnosis to amelioration of symptoms. This improves response rates, quality of life and results in significant savings for the healthcare systems.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

BeatsDigTherapeutics (2019)

Project SCALE: Tailored Digital Therapeutics for Neurological and Brain Disorders

Read More  

APS (2019)

On-site and On-demand Flexible Packaging System

Read More